AR048342A1 - FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) - Google Patents

FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)

Info

Publication number
AR048342A1
AR048342A1 ARP050101197A ARP050101197A AR048342A1 AR 048342 A1 AR048342 A1 AR 048342A1 AR P050101197 A ARP050101197 A AR P050101197A AR P050101197 A ARP050101197 A AR P050101197A AR 048342 A1 AR048342 A1 AR 048342A1
Authority
AR
Argentina
Prior art keywords
dosage forms
pharmaceutical dosage
glutamic acid
fthalimidoetoxi
acetile
Prior art date
Application number
ARP050101197A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of AR048342A1 publication Critical patent/AR048342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a formas de dosificacion farmacéuticas que hacen posible el suministro controlado y/o dirigido de una sustancia activa a regiones seleccionadas del tracto gastrointestinal de seres humanos o animales. Las formas de dosificacion farmacéuticas comprenden a la sustancia activa de ácido N-(2-(2-ftalimido-etoxi)-acetil)-L-alanil-D-glutámico (designado como LK 423). Se dan a conocer métodos de tratamiento de enfermedades inflamatorias cronicas del tracto gastrointestinal de seres humanos y/o animales, mediante el uso de dichas formas de dosificacion farmacéuticas. Proceso para la preparacion de dichas formas de dosificacion farmacéuticas.
ARP050101197A 2004-03-26 2005-03-28 FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) AR048342A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200400094 2004-03-26

Publications (1)

Publication Number Publication Date
AR048342A1 true AR048342A1 (es) 2006-04-19

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101197A AR048342A1 (es) 2004-03-26 2005-03-28 FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)

Country Status (15)

Country Link
US (1) US20100183714A1 (es)
EP (1) EP1734933B1 (es)
JP (1) JP2007530492A (es)
CN (1) CN1956707B (es)
AR (1) AR048342A1 (es)
AT (1) ATE468846T1 (es)
AU (1) AU2005226927B2 (es)
BR (1) BRPI0509271A (es)
CA (1) CA2559685A1 (es)
DE (1) DE602005021475D1 (es)
MY (1) MY145329A (es)
PE (1) PE20051163A1 (es)
RU (1) RU2375047C2 (es)
TW (1) TW200600121A (es)
WO (1) WO2005092295A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
WO2016196440A1 (en) * 2015-06-01 2016-12-08 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
WO2017223337A1 (en) * 2016-06-23 2017-12-28 Nutrivert Llc Methods to promote growth and improve feed conversion in animals
JP7750644B2 (ja) * 2016-11-09 2025-10-07 エンジーン，インコーポレイティド プログラム細胞死リガンド１の腸管発現
KR20190095936A (ko) * 2016-12-14 2019-08-16 프로제너티, 인크. 인테그린 저해제로의 위장관 질환의 치료
AU2017378393B2 (en) * 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CN110072519A (zh) * 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
PL4126040T3 (pl) 2020-03-26 2025-04-28 Nutrivert Inc. Lipofilowe enancjomery deacetyloglukozamino–muramylodipeptydu o aktywności przeciwzapalnej i wspomagającej wzrost

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210497B (en) * 1990-05-04 1995-04-28 Perio Prod Ltd Process for production of modified pectin
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
SI9011830B (sl) * 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
CN1956707A (zh) 2007-05-02
AU2005226927B2 (en) 2010-09-23
EP1734933A1 (en) 2006-12-27
TW200600121A (en) 2006-01-01
ATE468846T1 (de) 2010-06-15
JP2007530492A (ja) 2007-11-01
CA2559685A1 (en) 2005-10-06
PE20051163A1 (es) 2006-02-21
US20100183714A1 (en) 2010-07-22
CN1956707B (zh) 2010-12-29
BRPI0509271A (pt) 2007-09-04
MY145329A (en) 2012-01-31
WO2005092295A1 (en) 2005-10-06
EP1734933B1 (en) 2010-05-26
RU2375047C2 (ru) 2009-12-10
RU2006137660A (ru) 2008-05-10
AU2005226927A1 (en) 2005-10-06
DE602005021475D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
MA33023B1 (fr) Formulation d'anticorps
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
AR062167A1 (es) Sistema de administracion gastrorretentivo
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
AR048718A1 (es) Uso de formulaciones de meloxicam en medicina veterinaria
BRPI0509271A (pt) formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
ES2178961A1 (es) Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
DE602004017164D1 (de) Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
GT200600209A (es) Tratamiento de enfermedades usando un sistema mejorado de expresion regulada
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
AR053154A1 (es) Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina

Legal Events

Date Code Title Description
FB Suspension of granting procedure